# Baricitinib Therapy in COVID-19

> **NCT04358614** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fabrizio Cantini** · enrollment: 12 (actual)

## Conditions studied

- COVID
- Pneumonia

## Interventions

- **DRUG:** Baricitinib 4 MG Oral Tablet

## Key facts

- **NCT ID:** NCT04358614
- **Lead sponsor:** Fabrizio Cantini
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-16
- **Primary completion:** 2020-04-05
- **Final completion:** 2020-04-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358614, "Baricitinib Therapy in COVID-19". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04358614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*